The Italian Competition Authority initiates an investigation to ascertain an abuse of dominant position in the cancer drugs markets (Aspen)

With its decision of 19 November 2014, the Italian Competition Authority (“ICA” or the “Authority”) initiated an investigation into Aspa Pharma Trading Ltd and Aspen Italia S.r.l. (“Aspen”) - both belonging to the South African-based Aspen Group, a leading manufacturer of generic medicines - to ascertain whether it abused its dominant position in breach of Article 102 of the Treaty on the Functioning of the European Union (“TFEU”) by increasing the price of certain cancer drugs in Italy by between 250% and 1,500%. The four drugs under investigation are: Alkeran, Leukeran, Purinethol and Thioguanine (“Relevant Drugs”), which are all classified as “Class A” drugs and, therefore, refundable by the Italian National Health Service (“INHS”). The Authority initiated its investigation following: (i) the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

  • Bonelli Erede (Rome)
  • Bonelli Erede (Rome)

Quotation

Sara Lembo, Federica Puliti, The Italian Competition Authority initiates an investigation to ascertain an abuse of dominant position in the cancer drugs markets (Aspen), 19 November 2014, e-Competitions Notion of dominance, Art. N° 70807

Visites 251

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues